A heterologous vaccine regimen consisting of a first dose of the AstraZeneca vaccine and a second dose of the Pfizer vaccine induces a stronger immune response than a regimen consisting of two doses of the AstraZeneca vaccine.
by Gertrud U. Rey On July 20, 2020, Oxford University’s Jenner Institute and the pharmaceutical company AstraZeneca reported preliminary results from phase I/II clinical trials assessing the safety and efficacy of a vaccine candidate against SARS-CoV-2. The vaccine candidate, named AZD1222 (referred to in the publication as ChAdOx1 nCoV-19), consists of an adenovirus vector with an …
Preliminary phase I/II results of ChAdOx1 SARS-CoV-2 vaccine Read More »
